Information Provided By: 
Fly News Breaks for September 12, 2017
TEVA, COO
Sep 12, 2017 | 07:46 EDT
Stifel analyst Jonathan Block said Cooper Companies' (COO) agreement to buy Teva's (TEVA) Paragard intrauterine device for $1.1B is a good fit for Cooper's CSI franchise that helps it achieve greater scale and integration of this product "appears relatively straight forward." Paragard's favorable margin structure leads to significant accretion in year one, noted Block, who raised his price target on Cooper shares to $275 from $265 and keeps a Buy rating on the stock.
News For COO;TEVA From the Last 2 Days
